Program

Date

Session Type

Stream

LIVE Broadcast

2022 Diabetes Canada/CSEM Professional Conference

All sessions, except workshops, will be recorded and available on demand after conference for 6 months

Note: The 2022 Program is still being finalized, here are the sessions and speakers that are confirmed so far.

Wednesday, November 9, 2022

8:00 - 16:00

CSEM 16th Annual Endocrine Residents’ Day Review Course

Session Type: Workshop

Stream: CSEM

Learning Objectives: Agenda

At the end of this session, participants will be able to:
1. Review basic embryology and cell lines of pituitary development.

2. Describe reproductive cycle physiology.

3. Discuss the manifestations and diagnosis of delayed puberty.

4. Identify the causes of endocrine hypertension.

5. Outline the etiologies of hypocalcemia.

6. Compare approaches and management strategies for hypertriglyceridemia

13:30 - 16:30

Journey towards Indigenous Cultural Safety and Humility for HCPs

Jessie Newman RD
Fiona DeverauxRD, MSc, SDH Candidate

Session Type: Workshop

Stream: Indigenous Science & Content

At the end of this presentation, participants will be able to:
1. Build understanding of our shared history as Indigenous and non-Indigenous peoplesby walking through pre-contact, treaty-making, colonialism and Indigenous resistance

2. Support critical self-reflexivity: learning about who we are, who we are in relationship to Indigenous peoples, how we were socialized, and how that informs the stereotypes and biases we hold. Further, taking time to understand the harms and violences of Indigenous specific racism in health care.

3. Increase awareness of the intersection between land sovereignty, access to land, Indigenous food practices, and the impact of past and present colonial policies on the health of Indigenous peoples.

4. Explore how to createan Indigenous Cultural Safety learning journey to support aligning oneself and one’s practice to the recommendations outlined within the Truth and Reconciliation Commission Calls to Action, the BC In Plain Sight Report, and the United Nations Declaration onthe Rights of Indigenous Peoples

Registration for this workshop is now open!

Moderator

Jessie NewmanRD
13:30 - 16:30

To Pump or Not to Pump: Welcome to the World of Insulin Pumping

Leigh Caplan RN, MA, CDE
Jill ZweigRD, CDE

Session Type: Workshop

Stream: Clinical care and education

At the end of this presentation, participants will be able to:
1. Discuss the pros and cons of insulin pumps.

2. State the steps required for successful transition to insulin pumps.

3. Demonstrate programming a pump.

4. Discuss a case study applying learned knowledge.

13:30 - 16:30

Continuous Glucose Monitoring — Practical Approaches

Annabell Hall RN, MN, CDE
Catherine YuMD, FRCPC, MHSc
Patricia LemieuxMD
Bruce PerkinsMD, MPH, FRCP(C)

Session Type: Workshop

Stream: Clinical care and education

At the end of this presentation, participants will be able to:
1. Interpret and discuss appropriate actions to address intimidating CGM reports.

2. Use available clinical tools to address advanced clinical scenarios, i.e. the pregnant woman and the athlete.

3. Apply these strategies into practice.

13:30 - 16:30

The Transformative Diabetes Conversation

Session Type: Workshop

Stream: Clinical care and education

At the end of this presentation, participants will be able to:
1. Learn how psychotherapeutically informed interventions can be introduced and integrated into diabetes education.

2. Practice a Dozen simple interventions in small groups.

3. Consider how to combine interventions for optimum coaching conversations.

4. Discover how two steps can make your intervention memorable and transformative.

Moderator

Judy Bornais RN BA BScN MSc CDE
18:00 - 19:30

Eureka Moments: How rtCGM has Changed our Practice

Alanna Chambers RD, CDE
Jeremy GilbertMD, FRCPC
Elizabeth RosolowskyMD, MPH, FRCPC

Session Type: Symposia

Illustrated by real-life cases, Canadian experts in the clinical use of diabetes technology will share their practical tips and top EUREKA revelations that have made them more efficient, effective and empathetic, in their work with people with type 1 and type 2 diabetes.

At the end of this session, participants will be able to:

1. Recognize how the evidence for rtCGM has rapidly changed the standard of care and clinical practice

2. Apply practical tips that help people with diabetes use rtCGM easily and effectively

3. Reflect on their clinical practice and share revelations and learnings with people living with diabetes

This session is codeveloped with CSEM and Dexcom and planned to achieve scientific integrity and balance. Dexcom provided an unrestricted educational grant.

Chair

Ilana Halperin MD, FRCPC

Thursday, November 10, 2022

8:30 - 9:45

Barriers to Care for Indigenous Communities

Session Type: Plenary

Stream: All

10:15 – 11:45

Diabetes and Mental Health

Session Type: Concurrent

Stream: Clinical care and education

Jessica Kichler CDCES, PhD, CPsych

At the end of this presentation, participants will be able to:
1. Describe diabetes distress from the perspective of type 1 diabetes in childhood and adolescence.

2. Identify potential underlying psychosocial drivers for diabetes self-management issues in children/adolescents and their families.

3. Recognize the role of transitions in diabetes treatment planning throughout childhood and adolescence.

Tiffany ShepherdPhD, RPsych

At the end of this presentation, participants will be able to:
1. Develop awareness of emotional distress and well-being as overarching constructs.

2. Demonstrate understanding of the drivers of distress: problems of living based, disease-based, and psychopathology based.

3. Describe problems of living based distress in the context of COVID-19 and the use stress-management and resilience building interventions.

Tricia Tang PhD, RPsych

At the end of this presentation, participants will be able to:
1. Define what diabetes distress is.

2. Describe how to screen for diabetes distress in the clinic setting.

3. Learn how to explore the specific source and nature of diabetes distress.

David RobinsonMD, FRCPC, DLFAPA, FCPA

At the end of this presentation, participants will be able to:
1. Recognize the range of psychiatric conditions commonly seen in people living with diabetes.

2. Discuss the management of diabetes in individuals living with co-morbid psychiatric conditions.

3. Outline which medications to preferentially use and which ones to avoid in treating psychiatric symptoms in people with diabetes.

Moderator

Michael VallisPhD, RPysch
10:15 – 11:45

Role of Patient-Oriented Research in Developing New Models of Care

Diana Sherifali PhD

Session Type: Concurrent

Stream: Scientific

At the end of this presentation, participants will be able to:
1. Review the challenges of living with diabetes and the potential for mental health issues.

2. Describe how patient-oriented research can inform the co-design and implementing an integrated care model.

3. Describe an equitable and accessible technology enabled collaborative care (TECC) program for diabetes and mental health conditions.

10:15 – 11:45

Novel mechanisms of insulin secretion

Matthew Merrins PhD
Guy Rutter PhD

Session Type: Concurrent

Stream: Scientific

At the end of this presentation, participants will be able to:
1. Describe mitochondrial dynamics play a critical role in determining the response of pancreatic beta cells to glucose.

2. Explain pancreatic beta cells are hetergeneous in their responses to stimulation and defective mitochodrial function impairs their connectivity to restrict insulin secretion.

3. Describe incretins bypass defects in mitochondiral function in beta cells in type 2 diabetes.

10:15 – 11:45

Heart Failure & Diabetes

John Ussher PhD

Session Type: Concurrent

Stream: Scientific

At the end of this presentation, participants will be able to:
1. Discuss the concept that a significant portion of people in the early stages of type 2 diabetes have asymptomatic and often undiagnosed diastolic dysfunction.

2. Discuss the overlapping cardiac metabolic signatures between diabetes and heart failure.

3. Discuss whether early targeting of dysregulated cardiac energetics may be a novel approach to alleviate diastolic dysfunction and prevent HFpEF in diabetes.

12:15 - 13:15

Nuclear medicine: Lessons to learn for the endocrinologist

Session Type: Concurrent

Stream: CSEM

13:15 - 14:30

Optimizing cardiovascular risk reduction in people living with diabetes

John Mancini MD, FRCPC, FACP, FACC

Session Type: Plenary

Stream: Scientific

14:45 - 15:45

2022 Early Career Researcher Partnership Award Lecture

Session Type: Concurrent

14:45 - 15:45

Oral Abstracts - Indigenous Science and Content and Clinical Care and Education

Session: Concurrent

Stream: Indigenous Science & Content, Clinical Care and Education

1. Improving Equality in Outcomes for Indigenous Peoples with Type 2 Diabetes: Use of Special Authority Criteria.

2. Does the HNF-1a G319S variant in Anishininew communities confer a metabolic advantage to fasting?

3. Provincial Care Gaps in Frequency of Hemoglobin A1c Testing.

4. Rural Residence is Associated With a Delayed Trend Away From Sulfonylurea Use for Treatment Intensification of Type 2 Diabetes.

5. Inequities in Recurrent Admissions of Diabetic Ketoacidosis: Cause for Concern.

14:45 - 15:45

Pharmacological Management of Obesity in Diabetes

Session Type: Concurrent

Stream: Clinical care and education

Sue Pedersen MD FRCP(C) DABOM

At the end of this presentation, participants will be able to:
1. Understand the role of obesity pharmacotherapy in type 2 diabetes.

2. Understand the role of obesity pharmacotherapy in type 1 diabetes.

Trish Molberg BScPharm, APA, CDE, CRE, CTE

At the end of this presentation, participants will be able to:
1. Discuss the upstream approach: shifting our focus to treating obesity further upstream in T2DM.

Moderator

Kerry MansellBSP, PharmD, MBA
14:45 - 15:45

Under-recognized complications of diabetes

Session Type: Concurrent

Stream: Scientific

Claudia Gagnon MD

At the end of this presentation, participants will be able to:

1. Contrast the pathophysiology of bone disease and risk factors for fracture in Type 1 and Type 2 diabetes.

2. Evaluate fracture risk in people with Type 1 and Type 2 diabetes.

3. Discuss the prevention and treatment of diabetic bone disease.

Iliana Lega MD, MSc, FRCPC

At the end of this presentation, participants will be able to:
1. Provide on overview of cancer risk in people with diabetes in comparison with the general population.

2. Discuss the risk factors for cancer and the mechanisms behind increased risk in people living with diabetes.

3. Describe cancer screening recommendations to reduce cancer risk in people living with diabetes.

14:45 - 15:45

Collaborative Management of Graves' Ophthamology and New Treatment Approaches

George Kahaly MD, PhD

Session Type: Concurrent

Stream: CSEM

At the end of this presentation, participants will be able to:
1. Review evidence-based recommendations regarding the differentiation and assessment of disease activity, to aide in earlier diagnosis, classification, and treatment of Graves' orbitopathy.

2. Assess current evidence regarding the efficacy, safety, benefits, and limitations of conventional and new treatments for the treatment of Graves' orbitopathy.

3. Summarize best practices for treatment and referral that can improve the multidisciplinary co-management of patients with Graves' orbitopathy.

16:15 - 17:45

Thyroid Cancer: Controversies in RAI Dosing and Primary Surveillance

Session Type: Concurrent

Stream: CSEM

Shamir Chandarana MD
Jonathan Wasserman MD, PhD

At the end of this presentation, participants will be able to:
1. Highlight differences in presentation and outcome of advanced papillary thyroid carcinoma in children versus adults.

2. Discuss a rational approach to treatment planning and prioritization for children with advanced PTC.

3. Explore novel strategies for treatment of advanced PTC using RAI and systemic therapies.

Anna Sawka MD, PhD

At the end of this presentation, participants will be able to:
1. Discuss use of diagnostic tests in disease surveillance of low-risk papillary thyroid cancer treated with hemi-thyroidectomy (e.g. neck ultrasound, thyroglobulin measurement).

2. Discuss long-term TSH goals and consideration of levothyroxine treatment in low-risk papillary thyroid cancer treated with hemi-thyroidectomy.

3. Discuss some general survivorship concerns in low risk papillary thyroid cancer patients.

Moderator

Ralf PaschkeMD
16:15 - 17:45

Oral Abstracts - Clinical Care and Education

Stream: Clinical care and education

1. Reduction in 1-year mortality after a primary lower extremity amputation associated with diabetes or peripheral artery disease: What about the severity of the amputation?

2. Evaluating Health Disparities in a Pediatric Population with Type 1 Diabetes.

3. Addressing Diabetes Burden with Personalized Lifestyle and Habit Change Coaching.

4. Technology-Enabled Collaborative Care for Diabetes (TECC-D): Feasibility and Acceptability of a Disruptive Integrated Care Model.

5. Impact of Hybrid care on Care Delivery and Obstetrical Outcomes on Women with Gestational Diabetes.

6. Essential diabetes medicines and health outcomes in 127 countries.

Moderator

JM GambleBScPharm, PhD
16:15 - 17:45

Oral Abstracts - Basic Science

Stream: Scientific

1. Investigating Alpha and Beta Cell Phenotypes in Type 1 Diabetes.

2. Oxidative Stress and Early Cardiovascular Disease in Youth with Type 1 Diabetes: the CARDEA Study.

3. A Small Molecule Activator of Lyn Improves the Outcomes of Islet Transplantation In Mice.

4. Single-cell RNA Sequencing Reveals a Role for Reactive Oxygen Species and Peroxiredoxins in Fatty Acid-induced Rat ß-cell Proliferation.

16:15 - 17:45

Putting Theory into Action: Supporting Behaviour Change in Individuals at Risk or living with Type 2 Diabetes

Enza Gucciardi PhD
Mary Jung PhD

Session Type: Concurrent

Stream: Scientific

16:15 - 17:45

Diabetes and Nutrition

Session Type: Concurrent

Stream: Clinical care and education

Jenna Walsh RD, CDE

At the end of this presentation, participants will be able to:
1. Describe various options for using hormone replacement to induce pubertal changes in boys.

2. Describe various options for hormone replacement to induce pubertal changes in girls.

3. Describe the goals for hormone replacement in individuals presenting with delayed puberty.

Michael Mindrum MD, FRCPC

At the end of this presentation, participants will be able to:
1. Describe a multidisciplinary approach to using low carb/high fat ketogenic diets.

2. Through case studies, Illustrate adjustments in medications that need to be considered.

3. Address potential benefits and concerns about ketogenic diets in the setting of type 2 diabetes.

Moderator

Kim YoungRD, MSH, CDE
16:15 - 17:45

Hunger was never absent: How residential school diets shaped current patterns of diabetes among Indigenous peoples in Canada

Session Type: Concurrent

Stream: Indigenous Science & Content

18:45 - 20:15

Beyond A1C: The Emerging Role of Time in Range

Ilana Halperin MD, FRCPC
Anne-Marie Carreau MD, MSc, FRCPC
Barbara Cleave RN, CDE

Session Type: Symposia

This presentation will investigate continuous glucose monitoring metrics and patterns, the impact of time in range.
At the end of this session, participants should be able to:

1. Describe the impacts of glycemic variability on patient lifestyle, activity and quality of life.

2. Describe the implications of recent time-in-range studies.

3. Communicate the use of continuous glucose monitoring with patients and a multidisciplinary care team.

This program was co-developed and planned by CSEM and Sanofi to achieve scientific integrity, objectivity, and balance. Sanofi provided an unrestricted educational grant.

Moderator

Jean-Franćois Yale MD, FRCPC

Friday, November 11, 2022

7:00 - 8:20

Straight to the Source: Early Glucose AND weight control with dual GIP/GLP-1 receptor agonism in people with T2D and/or obesity 

Mahua Ghosh MD
Lori Berard RN, CDE
Lisa Maks RN, CDE

Session Type: Symposia

Kick off your morning with an energizing, co-developed, accredited program discussing the impact of early, stringent glucose and weight control on the progression of type 2 diabetes (T2D) and the potential of dual GIP/GLP-1 receptor agonist therapy.

At the end of this session, participants should be able to:

1. Explain the impact of early stringent glucose and weight control on preserving the long-term health of people with type 2 diabetes.

2. Describe the mechanism of action, efficacy, safety and tolerability of dual GIP/GLP-1 receptor agonist therapy for patients living with type 2 diabetes and/or obesity.

3. Identify patients who could benefit from dual GIP/GLP-1 receptor agonist therapy.

This session is codeveloped with CSEM and Lilly and planned to achieve scientific integrity and balance. Lilly provided an unrestricted educational grant.

Moderator

Sue Pedersen MD, FRCPC
8:30 - 9:45

Future of Obesity Medications

Daniel Drucker MD

Session Type: Plenary

Stream: All

At the end of this presentation, participants will be able to:
1. Review the history of obesity medicines.

2. Compare currently approved medicines for obesity.

3. Highlight the investigational pipeline of medical therapies for obesity.

10:15 - 11:45

Hormone Treatments Throughout the Lifespan and Across Genders

Session Type: Concurrent

Stream: CSEM

Laura Stewart MD, FRCPC

At the end of this presentation, participants will be able to:
1. Review the diagnostic criteria for premature ovarian insufficiency and early menopause.

2. Develop an approach to hormonal management of POI.

3. Understand the specificity of hormonal treatment for this specific group.

Raymond Fung MD, FRCPC

At the end of this presentation, participants will be able to:
1. Describe the risks and benefits of hormone therapy in the older trans and non binary individual.

2. Appreciate the factors which contribute to the negative health outcomes specific to trans and nonbinary older adults.

3. Formulate a patient centred approach to providing gender affirming hormone therapy in the older trans and nonbinary older adult.

Jeanne Bouteaud MD, FRCPC

Moderator

Dan MetzgerMD, FRCPC
10:15 - 11:45

Stem cell therapies for diabetes: What’s new and what’s on the horizon? 

Andrew Pepper PhD

Session Type: Concurrent

Stream: Scientific

At the end of this presentation, participants will be able to:
1. Discuss the current status of beta cell replacement therapy for the treatment of T1D.

2. Describe clinical trials of stem cell derived islets.

3. Understand new advances and technologies in stem cell-derived islet transplantation that improve graft function.

10:15 - 11:45

Translational models systems and new tools for the study of diabetes

Session Type: Concurrent

Stream: Scientific

Jonathan Rocheleau PhD

At the end of this presentation, participants will be able to:
1. Discuss the concept that a significant portion of people in the early stages of type 2 diabetes have asymptomatic and often undiagnosed diastolic dysfunction.

2. Discuss the overlapping cardiac metabolic signatures between diabetes and heart failure.

3. Discuss whether early targeting of dysregulated cardiac energetics may be a novel approach to alleviate diastolic dysfunction and prevent HFpEF in diabetes.

Mahla Poudineh PhD

At the end of this presentation, participants will be able to:
1. Learn about a new real-time ELISA assay that enables continuous insulin measurement.

2. Learn about a new transdermal technology for tracking diabetes in a wearable setting.

3. Learn about our future direction in developing next-generation diabetes technologies.

10:15 - 11:45

Chronic Kidney Disease in Diabetes: Update

Session Type: Concurrent

Stream: Clinical care and education

Alice Cheng MD, FRCPC

At the end of this presentation, participants will be able to:
1. List the unique considerations for glycemic management in people living with diabetes and severe kidney dysfunction.

2. Name antihyperglycemic therapies that are safe to use in those with severe kidney dysfunction.

3. Adjust antihyperglycemic therapies in those with severe kidney dysfunction, including dialysis, to avoid adverse effects and hypoglycemia.

Louis Girard MD, MBT, FRCPC

At the end of this presentation, participants will be able to:
1. Describe the pathophysiology of hyperfiltration in diabetic nephropathy and to link this to current screening guidelines.

2. Understand how SGLT2i address hyperfiltration in kidney disease.

3. Update existing knowledge of SGLT2i kidney outcomes with the newest literature and clinical trials.

George Bakris FAHA,FASN

At the end of this presentation, participants will be able to:
1. Become familiar with novel agents that slow nephropathy progression independent of glucose control.

2. Learn how to use different classes of drugs to slow nephropathy progression.

3. Describe adverse effects and their management of the novel class of nonsteroidal mineralocorticoid receptor antagonists.

Moderator

James Kim MBBCh, PgDip
10:15 - 11:45

Cardiovascular risk reduction after gestational diabetes

Kara Nerenberg MD, MSc
Kaberi Dasgupta MD, MSc

Moderator

Ariane GodboutMD, FRCPC

Session Type: Concurrent

Stream: Clinical care and education

At the end of this presentation, participants will be able to:
1. Describe the impacts of pregnancy related disorders (including gestational diabetes) on a female’s future cardiometabolic health.

2. Identify simple postpartum vascular risk reduction strategies.

3. Understand the key roles that interdisciplinary clinicians play in improving cardiovascular health after pregnancy.

12:15 - 13:15

Spotlight on Up and Coming Scientists

Stream: CSEM

13:15 - 14:30

CPG Update

Session Type: Plenary

Stream: Clinical care and education

Harpreet Bajaj MD, MPH, ECNU, FACE

At the end of this presentation, participants will be able to:
1. Describe the new revision process for Diabetes Canada clinical practice guidelines.

2. Share the context, methods, recommendations and implementation tools for a new “Remission of type 2 diabetes” chapter, the first of its kind in Canada.

3. Outline recommendations from the two CPG chapter updates (mental health and hypoglycemia) and a new “DIY Insulin Pump Therapy in type 1 diabetes” position statement.

Ilana Halperin MD, MSc, FRCPC

At the end of this presentation, participants will be able to:
1. Describe why a position paper on DIY AID is needed including current HCP and PWD perspectives on the technology.

2. Apply a legal and ethical framework that can support clinicians to support patients using DIY AID.

3. Understand some key similarities and differences between DIY AID and commercial AID systems.

Dylan Mackay PhD

At the end of this presentation, participants will be able to:
1. Describe the new Diabetes Canada "Remission of type 2 diabetes” chapter.

2. Discuss the concept of type 2 diabetes remission.

3. Understand the recommendations from the new “Remission of type 2 diabetes” chapter.

Susie Jin RPh, CDE, CRE
Iliana Lega MD, MSc, FRCPC    
14:45 - 15:45

Oral Abstracts - Late-breaking

Moderator

JM GambleBScPharm, PhD

Stream: All

14:45 - 15:45

Adrenal Hypertension: Differential Diagnosis, Monitoring & Surveillance

Session Type: Concurrent

Stream: CSEM

Dan Holmes MD, FRCPC

At the end of this presentation, participants will be able to:
1. Describe the two most common ways to biochemically assess renin.

2. Learn the tools to convert renin activity and renin mass between multiple unit systems.

3. Define how renin measurement can be affected by medications and specimen handling.

Ari Morgenthau MD, FRCPC

At the end of this presentation, participants will be able to:
1. Recognize the genetic causes of adrenal hypertension​.

2. Understand when and how to send for genetic testing​.

3. Understand the basics of how to interpret the genetic test results and when to as for help from a medical geneticist.​

Jeannette Goguen MD, FRCPC

Moderator

Naomi SeverinMD, FRCPC
14:45 - 15:45

Sleep and Diabetes

Charles Samuels MD, CCFP, DABSM

Session Type: Concurrent

Stream: Clinical care and education

At the end of this presentation, participants will be able to:
1. Clinically assess a patient for sleep behaviors, sleep health and sleep disorders.

2. Initiate basic and important behavioral measures to improve sleep health.

3. Determine when a referral to a sleep specialist is necessary and important.

4. Articulate the limitations of community based CPAP company care.

14:45 - 15:45

Immunometabolic dysfunction in diabetes

Ramon Klein-Geltink PhD
Sue Tsai PhD

Session Type: Concurrent

Stream: Scientific

At the end of this presentation, participants will be able to:
1. Discuss the impact of hyperinsulinemia on immune function.

2. Describe how adaptive immune cells become activated during obesity and their contribution to type 2 diabetes.

3. Discuss how obesity-related insulin resistance reciprocally dysregulates adaptive immune function.

16:15 - 17:45

Diabetes and Bariatric Surgery

Session Type: Concurrent

Stream: Clinical care and education

Stephanie Camerion RD

At the end of this presentation, participants will be able to:
Outline key nutrition recommendations for bariatric surgery preparation and postop.

1. Highlight nutrition concerns and challenges.

2. Explain psychological screening practices.

3. Discuss supports and challenges.

Jo Telfer PhD RPsych

At the end of this presentation, participants will be able to:
1. Understand the complexity and chronicity of obesity.

2. Identify appropriate mental health screens and how mental health affects bariatric surgery outcomes.

3. Identify the challenges of helping people change their relationship with food.

Moderator

Anne McLaughlin
16:15 - 17:45

Oral Abstracts - Clinical Science

Stream: Scientific

1. Once-Weekly Semaglutide 2.4 mg Improved Glucose Metabolism and Prediabetes in Adults with Overweight/Obesity in the STEP 1 Trial.

2. Identifying Blood Biomarkers for Type 2 Diabetes Subtyping: A Report from the ORIGIN Trial.

3. Insulin-Sparing Effects of Oral Semaglutide: an Analysis of PIONEER 8.

4. Patterns of Metformin Use and A1C Trends among Patients with Incident Type 2 Diabetes.

5. Predicting Real-World Severe Hypoglycemia Risk in Diabetes (iNPHORM, USA).

16:15 - 17:45

Oral Abstracts

Moderator

Vicki MunroMD, FRCPC

Stream: CSEM

1. Prospective Evaluation of Molecular Testing of Indeterminate Thyroid Nodule Cytologies Following Diagnostic Pathway Optimization.

2. Severity of albuminuria increases risk of fragility fractures independent of eGFR: a population-based analysis.

3. Mechanisms of β-cell Proliferation in Response to Insulin Resistance during Puberty.

4. The Impact of Bariatric Surgery on Assisted Reproductive Technology Outcomes: A Systematic Review.

5. Adrenal Insufficiency: Investigating Prevalence and Healthcare Utilization Using Administrative Data.

6. Polycystic Ovary Syndrome is associated with Increased Incidence of Co-morbidities in a Canadian Population Cohort.

16:15 - 17:45

Beyond the beta cell: The other endocrine islet cells

Session Type: Concurrent

Stream: Scientific

Savita Dhanvantari PhD

At the end of this presentation, participants will be able to:
1. Recognize the under-appreciated role of hyperglucagonemia in diabetes.

2. Identify the intracellular compartments in the alpha cell through which glucagon is transported.

3. Discuss how abnormal glucagon secretion may be associated with altered intracellular transport of glucagon.

Vincent Poitout DVM, PhD

At the end of this presentation, participants will be able to:
1. Describe the regulation of islet hormone secretion by somatostatin and the contribution of the delta cell to glucose homeostasis.

2. Identify the mechanisms by which the fatty-acid receptor regulates somatostatin secretion from the delta cell.

3. Define the regulation of somatostatin action by regulators of G protein signaling in islets.

Moderator

Patrick MacDonald
18:45 - 20:15

The Hidden Risk Marker in Diabetes: Triglycerides and Cardiovascular Risk

Akshay Jain MD, FRCPC, FACE, CCD, ECNY, DABIM, DABOM
Sandra Cooke-Hubley MD
Claudia Bucci

Session Type: Symposia

At the end of this session, participants will be able to:

1. Recognize the heightened risk posed by elevated triglycerides in the patient with diabetes with concomitant risk factors or with ASCVD.

2. Examine the evidence reading the cardiovascular benefits of icosapent ethyl and its mechanisms of action.

3. Explain practical issues in patient selection and follow up when prescribing icosapent ethyl to patients with diabetes at increased CV risk.

This program was co-developed and planned by CSEM, CCRN (the Canadian Collaborative Research Network) and HLS Therapeutics to achieve scientific integrity, objectivity, and balance. HLS Therapeutics provided an unrestricted educational grant.

Moderator

Milan Gupta MD, FRCPC, FACC

Saturday, November 13, 2022

8:00 - 9:15

Brown Adipose Tissue

Session Type: Concurrent

Stream: CSEM

Gregory Steinberg MD

At the end of this presentation, participants will be able to:
1. Review how brown adipose tissue oxidizes fatty acids and carbohydrates.

2. Discuss mechanisms regulating brown adipose tissue function in obesity and diabetes.

3. Detail how brown adipose tissue may exert positive effects on blood glucose homeostasis.

Andre Carpentier MD

At the end of this presentation, participants will be able to:
1. Review the definition of brown adipose tissue.

2. Detail the effect of brown adipose tissue in energy expenditure and energy substrate homeostasis in humans.

3. Discuss the dysregulation of this tissue functions in obesity and diabetes.

Moderator

Donna VinePhD
8:00 - 9:15

Diabetes in the Child/Adolescent

Lindsay Booker PhD
Juliana Walker MEd, MSc

Moderator

Leta PhilpBScN, RN, CDE

Session Type: Concurrent

Stream: Clinical care and education

At the end of this presentation, participants will be able to:
1. Recognize the role of experiential avoidance and cognitive fusion in non-adherence.

2. Understand the objective of cognitive flexibility using acceptance, acceptance, mindfulness and cognitive defusion.

3. Identify key elements of parental support and the parent-adolescent relationship in treatment adherence and disease management.

8:00 - 9:15

Diabetic Foot Diseases: Illuminating the Path to Amputation Prevention for The Diabetes Healthcare Team Screening and beyond

Virginie Blanchette MD
Janet Kuhnke RN, BA, BScN, MS, NSWOC

Session Type: Concurrent

Stream: Clinical care and education

8:00 - 9:15

Hypoglycemia: Risk Considerations and New Strategies

Remi Rabasa-Lhoret MD, PhD
Stewart Harris MD, MPH, FCFP, FACPM
Alexandria Ratzki-Leewing PhD

Session Type: Concurrent

Stream: Scientific

9:30 - 10:30

Isabel Lockerbie Address: Life's A Gamble - Lessons Learned Living with Diabetes

Anissa Gamble MSc, DDS candidate

Session Type: Plenary

Stream: Clinical care and education

At the end of this presentation, participants will be able to:
1. Describe diabetes life lessons from the perspective of a high-performance athlete and researcher.

2. Discuss the importance of including the larger support network in the diabetes care team.

3. Analyze how and why diabetes management programs should be personalized to ensure suitability for individual lifestyle needs.

9:30 - 10:30

Pituitary Session: Treatment Resistant Prolactinomas; Infiltrative Diseases of the Pituitary

Ali Imran MBBS, FRCPC
Fabienne Langlois MD

Session Type: Concurrent

Stream: CSEM

At the end of this presentation, participants will be able to:
1. Detail the causes and characteristics of infiltrative disease affecting the pituitary.

2. Choose the appropriate investigations and indications for biopsy/surgery.

3. Discuss the appropriate management and use of glucocorticoids.

10:45 - 12:00

Pros/Cons of Pre-Op Steroids for Pituitary Surgery

Jessica Mackenzie-Feder MD, FRCPC
Christopher Tran MD, FRCPC

Session Type: Concurrent

Stream: CSEM

At the end of this presentation, participants will be able to:
1. Compare the benefits and risks of providing versus withholding perioperative corticosteroids to patients undergoing transsphenoidal pituitary surgery.

2. Identify nuances in certain cases that would make one approach more appropriate than the alternative approach.

3. Discuss their current practice with multi-disciplinary teams to ensure best practice is being followed within the specific context of each centre.

10:45 - 12:00

CanDIP Debate - Medical therapy is more effective than lifestyle therapy in the prevention of diabetes post-GDM (PRO)

Lorraine Lipscombe (CON) MD, MSc
Caroline Kramer (PRO) MD, PhD

Moderator

Ariane GodboutMD, FRCPC

Session Type: Concurrent

At the end of this presentation, participants will be able to:
1. Understand the evidence for diabetes prevention after GDM.

2. Describe the advantages and limitations of pharmacotherapy and lifestyle/behavioural interventions.

3. Compare pros and cons of pharmacotherapy versus lifestyle/behavioural interventions.

10:45 - 12:00

Molecular mechanisms of insulin signalling and resistance in obesity and diabetes

Session Type: Concurrent

Stream: Scientific

Amira Klip PhD

At the end of this presentation, participants will be able to:
1. Describe how muscle cells directly respond to excess saturated fat, affecting insulin signalling and beyond.

2. Explain how the body responds to excess saturated fat, with particular focus on innate immune cells.

3. Describe how immune cells in the bone marrow respond to high fat diets.

Andre Marette PhD

At the end of this presentation, participants will be able to:
1. Describe the mechanisms by which nutrient satiation promotes insulin resistance.

2. Discuss the role of inflammation in the development of insulin resistance.

3. Discuss novel targets (e.g. SHP-1) for potential insulin resistance therapies.